This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Interventions
The sensitivity and specificity of several strategies of screening for combinations of different markers were evaluated. Two strategies were the current English manual grading and the current Scottish manual grading. Other strategies were another manual grading (Strategy 16); a fully automated annotation grading with the inclusion of visual acuity; and a strategy with the inclusion of optical coherence tomography (OCT) before referral (Strategy 8). The strategies were based on the detection of exudates or blot haemorrhages; microaneurysms or dot haemorrhages; and visual acuity measured by the log of the minimum angle of resolution.
Location/setting
UK/out-patient care.
Methods

Analytical approach:
The cost-effectiveness analysis was based on one clinical study. Two analyses were conducted. For the short-term analysis, a decision-tree was used, and for the long-term analysis, a Markov micro-simulation was used. In the Markov model, six health states were defined by the visual acuity in the better seeing eye. The authors stated that a UK NHS perspective was adopted.
Effectiveness data:
The sensitivity and specificity of the different screening strategies for the presence of macular oedema in at least one eye were from a clinical study in which the diabetic retinopathy tests and OCT were applied to every patient and OCT was the reference standard. Full details of this UK-wide, multicentre, prospective, observational cohort study were presented. There was a maximum of four weeks between the retinal photograph and the OCT, with 89% of optical coherence scans conducted on the same day as the retinal photograph. In separate analyses, the sensitivity and specificity were adjusted to account for prevalence in subgroups within the normal population. In the long-term model, the probabilities of moving between visual acuity states were from published UK cohort studies.
Monetary benefit and utility valuations:
Utility values were applied to the different visual acuity health states. A review of the literature was conducted, and suitable weights were obtained from one UK study. The utilities were estimated directly using the standard gamble method.
Measure of benefit:
For the short-term analysis, the number of cases detected was the measure of benefit. For the long-term analysis, the quality-adjusted life-year (QALY) was used. QALYs were discounted at a rate of 3.5% per annum.
Cost data:
The costs of screening, referral and treatment were included. Screening costs were estimated by a survey of participating centres, and included all equipment, staff, space and overheads. Individual inputs were valued using appropriate unit costs from three of the participating screening centres. The total was divided by the number of patients screened to produce per person costs. Automated annotation grading was assumed not to increase the grading costs. The treatment and social costs of macular oedema and legal blindness were from published UK sources. The price year was 2009 to 2010 and the costs were presented in UK £. They were discounted at a rate of 3.5% per annum.
Analysis of uncertainty:
One-way sensitivity analyses were conducted for the key parameters. Probabilistic sensitivity analysis was conducted to characterise the overall uncertainty in the model inputs.
Results
The costs and outcomes were presented separately. The results were presented using English and Scottish screening and referral costs.
Each strategy was compared with the Scottish manual strategy. Strategy 16 (other manual grading) had an incremental cost-effectiveness ratio of £1,579 using English costs or £985 using Scottish costs per case detected.
Each strategy plus OCT at screening was compared with the Scottish manual strategy plus OCT. Strategy 16 plus OCT had a ratio of £639 using English costs or £528 using Scottish costs. Strategy 8 (with OCT before referral) plus OCT at screening had a ratio of £1,510 using English costs or £1,360 using Scottish costs per case detected. Extensive deterministic and probabilistic sensitivity analysis results were presented.
